Introduction
disease of cardiac sarcomeric, HCM
DISEASE, LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION
Small molecule inhibitors are an emerging class of novel therapeutic agents that inhibit the function of specific proteins with the potential for neutralizing deleterious downstream effectsHCM is a disease of cardiac sarcomeric proteins with identified mutations in cats affecting the One contributing factor to morbidity and mortality of HCM in human patients is the presence of left ventricular outflow tract obstruction (LVOTO)Evidence is currently lacking for therapies with proven efficacy in delaying progression of disease or conferring survival benefits in subclinical human and feline HCM patientsThe aim of this study was to characterize the pharmacodynamic effects of a single oral administration of two dose strengths (0.3 mg/kg and 1 mg/kg) of the next-in-class cardiac myosin inhibitor, 